A Phase 3, Randomized, Double-blind, Active Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar (BMS-298585) Compared to Pioglitazone in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
A Phase 3, Randomized, Double-blind, Active Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Muraglitazar (BMS-298585) Compared to Pioglitazone in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
The purpose of this study is to compare Muraglitazar and Pioglitazone in patients with Type 2 Diabetes. Both the safety and blood sugar lowering effects of these treatments will be studied.
Inclusion Criteria:
Exclusion Criteria:
Charlotte Harbour, Florida, United States
Cantonville, Maryland, United States
Buenos Aires, Buenos Aires, Argentina
Chacabuco, Chaco Province, Argentina
Freemantle, Western Australia, Australia
B. Rodolfo Teofilo, CearĆ”, Brazil
Cerq. Cesar, SĆ£o Paulo, Brazil
Guama, SĆ£o Paulo, Brazil
Rua Maestro, SĆ£o Paulo, Brazil
Ruo Maestro Cardim, SĆ£o Paulo, Brazil
Santiago, Valparaiso, Chile
Taoyuan Hsien, Taiwan
Kong Kaen, Thailand
Taipei City, Thailand
Dniepropetrovsk, Ukraine